Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
Yoshie Hasegawa, Hirokazu Tanino, Jun Horiguchi, Daishu Miura, Takashi Ishikawa, Mitsuhiro Hayashi, Shintaro Takao, Seung Jin Kim, Kazuhiko Yamagami, Masaru Miyashita, Muneharu Konishi, Yasushi Shigeoka, Masato Suzuki, Tetsuya Taguchi, Tomoyuki Kubota, Kouhei Akazawa, Norio Kohno, JONIE Study Group, Nana Rokutanda, Takahiro Tanaka, Sachiko Mizumoto, Kazuyuki Wakita, Tomonari Kunihisa, Kimito Yamada, Hiroshi Kaise, Koichi Hirokaga, Kaori Tane, Teruhisa Sakurai, Akimasa Nishimura, Yoshie Hasegawa, Hirokazu Tanino, Jun Horiguchi, Daishu Miura, Takashi Ishikawa, Mitsuhiro Hayashi, Shintaro Takao, Seung Jin Kim, Kazuhiko Yamagami, Masaru Miyashita, Muneharu Konishi, Yasushi Shigeoka, Masato Suzuki, Tetsuya Taguchi, Tomoyuki Kubota, Kouhei Akazawa, Norio Kohno, JONIE Study Group, Nana Rokutanda, Takahiro Tanaka, Sachiko Mizumoto, Kazuyuki Wakita, Tomonari Kunihisa, Kimito Yamada, Hiroshi Kaise, Koichi Hirokaga, Kaori Tane, Teruhisa Sakurai, Akimasa Nishimura
Abstract
Purpose: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway. Its benefit for the prevention of skeletal complications due to bone metastases has been established. However, the antitumor efficacy of ZOL, although suggested by multiple preclinical and clinical studies, has not yet been clinically proven. We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT).
Methods: Asian patients with HER2-negative invasive breast cancer were randomly assigned to either the CT or CT+ZOL (CTZ) group. One hundred and eighty-eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to April 2012, and 180 patients were assessed. All patients received four cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly. ZOL (4 mg) was administered three to four times weekly for 7 weeks to the patients in the CTZ group. The primary endpoint was the pathological complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen. Safety was assessed in all patients who received at least one dose of the study drug.
Results: This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), respectively (one-sided chi-square test, p = 0.068), though the additional efficacy of zoledronic acid was not demonstrated statistically. The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, respectively (one-sided Fisher's exact test, p = 0.071), and that in patients with triple-negative breast cancer was 35.3% and 11.8% in the CTZ and CT groups, respectively (one-sided Fisher's exact test, p = 0.112). Thus the addition of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple-negative breast cancer. Further investigation is warranted.
Trial registration: University Hospital Medical Information Network. UMIN000003261.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–428. 10.1016/s1470-2045(10)70054-1
- Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog. 2011;10:2 10.4103/1477-3163.75723
- Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010–01). Ann Oncol. 2014;25:998–1004. 10.1093/annonc/mdu102
- Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398–405. 10.1093/annonc/mds277
- Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, et al. Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Res. 2013;73:S4–07. 10.1158/0008-5472.sabcs13-s4-07
- Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, et al. Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Res. 2013;73:S4–07. 10.1158/0008-5472.sabcs13-s4-07
- Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011;127:429–438. 10.1007/s10549-011-1429-y
- Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365:1396–1405. 10.1056/NEJMoa1105195
- Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010;102:1099–1105. 10.1038/sj.bjc.6605604
- Fehm T, Zwirner M, Wallwiener D, Seeger H, Neubauer H. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer. 2012;12:308 10.1186/1471-2407-12-308
- Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4:30–34.
- Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–691. 10.1056/NEJMoa0806285
- Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631–641. 10.1016/s1470-2045(11)70122-x
- Green JR, Guenther A. The backbone of progress—preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011;77(Suppl 1):S3–s12. 10.1016/s1040-8428(11)70003-8
- Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314–3321. 10.1200/jco.2005.05.116
- Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer. 2010;102:1010–1017. 10.1038/sj.bjc.6605579
- Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010;126:522–532. 10.1002/ijc.24756
Source: PubMed